Abstract

BackgroundAboriginal children in remote Australia have high rates of complicated middle ear disease associated with Streptococcus pneumoniae and other pathogens. We assessed the effectiveness of pneumococcal vaccination for prevention of otitis media in this setting.MethodsWe compared two birth cohorts, one enrolled before (1996–2001), and the second enrolled after introduction of 7-valent pneumococcal conjugate and booster 23-valent polysaccharide vaccine (2001–2004). Source populations were the same for both cohorts. Detailed examinations including tympanometry, video-recorded pneumatic otoscopy and collection of discharge from tympanic membrane perforations, were performed as soon as possible after birth and then at regular intervals until 24 months of life. Analyses (survival, point prevalence and incidence) were adjusted for confounding factors and repeated measures with sensitivity analyses of differential follow-up.ResultsNinety-seven vaccinees and 51 comparison participants were enrolled. By age 6 months, 96% (81/84) of vaccinees and 100% (41/41) of comparison subjects experienced otitis media with effusion (OME), and by 12 months 89% and 88% experienced acute otitis media (AOM), 34% and 35% experienced tympanic membrane perforation (TMP) and 14% and 23% experienced chronic suppurative otitis media (CSOM). Age at the first episode of OME, AOM, TMP and CSOM was not significantly different between the two groups. Adjusted incidence of AOM (incidence rate ratio: 0.88 [95% confidence interval (CI): 0.69–1.13]) and TMP (incidence rate ratio: 0.63 [0.36–1.11]) was not significantly reduced in vaccinees. Vaccinees experienced less recurrent TMP, 9% (8/95) versus 22% (11/51), (odds ratio: 0.33 [0.11–1.00]).ConclusionResults of this study should be interpreted with caution due to potential bias and confounding. It appears that introduction of pneumococcal vaccination among Aboriginal infants was not associated with significant changes in prevalence or age of onset of different OM outcomes or the incidence of AOM or TMP. Vaccinees appeared to experience reduced recurrence of TMP. Ongoing high rates of complicated OM necessitate additional strategies to prevent ear disease in this population.

Highlights

  • Aboriginal children in remote Australia have high rates of complicated middle ear disease associated with Streptococcus pneumoniae and other pathogens

  • Among Aboriginal infants, Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis have been isolated from 57%, 34% and 4% of tympanic membrane perforation (TMP) respectively, with H. influenzae and S. pneumoniae co-infection in 28% of cases[4]

  • We found that infant pneumococcal vaccination in remote Aboriginal communities was associated with, albeit with marginal significance: a) Little effect on cumulative proportions of participants experiencing, or time to first episode of otitis media with effusion (OME), acute otitis media (AOM), TMP, or chronic suppurative otitis media (CSOM)

Read more

Summary

Introduction

Aboriginal children in remote Australia have high rates of complicated middle ear disease associated with Streptococcus pneumoniae and other pathogens. We assessed the effectiveness of pneumococcal vaccination for prevention of otitis media in this setting. Young Aboriginal children in remote Australia have a 24% prevalence of tympanic membrane perforation (TMP) and 15%[1] to 24%[2] prevalence of chronic suppurative otitis media (CSOM). We thought that 7PCV might be even more effective in populations with a high burden of severe otitis (Australian Aboriginal children and others with substantial prevalence of CSOM [11,12,13,14]). We compared: 1) time to develop otitis media with effusion (OME) and other OM outcomes, 2) OM prevalence outcomes and 3) OM incidence outcomes in two birth cohorts of Aboriginal infants, before and after introduction of pneumococcal vaccination

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call